12 results about "Hepatic parenchymal cell" patented technology

The application discloses a preparation method and application of large-size human liver organoids, and belongs to the technical field of cell culture. In the application, 2D culture mature human primary liver parenchymal cells with different cell amounts are resuspended by using a hepatocyte maturation medium HIM, and are added into a U-shaped bottom 96-hole plate for low-oxygen static culture. After the cells are aggregated, the cells are cultured in normal oxygen and are shaken, so that large-size human liver organoids with different cell contents are prepared. The method does not need biological materials, and can induce human primary liver parenchymal cells to self-assemble and construct functional liver organoids with high uniformity in scale through specific culture conditions. The method solves the problems of large batch difference, high heterogeneity and dedifferentiation in the prior art, and can be widely applied to drug hepatotoxicity testing, in-vitro modeling of liver diseases and development of a bioartificial liver system.

The present application relates to a kind of FAPi, FAPi intermediate, FAPi modified HSP47siRNA loaded lipid nanoparticles and its application, belong to the field of biological medicine.The inventor constructs a kind of HSP47siRNA loaded lipid nanoparticles (FAPi-LNP / siHSP47) of Fibroblast activation protein inhibitor (FAPi) modification in view of the problems of high morbidity of existing technology liver fibrosis, so far no medicine, and ordinary LNP mainly target delivery to liver parenchymal cell after intravenous injection, and cannot enter the activated hepatic stellate cell (HSC) that plays a key role in the development of liver fibrosis.The expression of HSP47 can be effectively knocked down by the mediation of the high expression of Fibroblast activation protein on the surface of activated HSC, and the content of liver fibrosis marker protein a-SMA can be reduced.Compared with LNP without FAPi modification, FAPi-LNP / siHSP47 actively targets activated HSC after entering liver tissue, enters cell under the mediation of FAP, significantly knocks down the expression of HSP47, reduces collagen deposition, and significantly improves liver fibrosis.

This invention belongs to the field of biomedical technology and discloses the use of catalpol and mesenchymal stem cells in the preparation of drugs for treating liver fibrosis, wherein the concentration of catalpol is 50–200 μM and the concentration of exosomes is 20–50 μg / mL. Simultaneously, this invention constructs a spatially resolved liver fibrosis chip model based on GelMA hydrogel, integrating Kupffer-like cells, hepatic stellate cells, hepatic parenchymal cells, and endothelial cells through a layered sequential seeding strategy, achieving high-precision biomimicry of the liver fibrosis microenvironment. In vitro chip and in vivo animal experiments confirmed that this combined approach can significantly inhibit the expression of collagen synthesis-related genes, improve liver function indicators, and effectively reduce collagen deposition; its anti-fibrotic efficacy is significantly better than the simple superposition of the effects of single components, exhibiting a clear synergistic effect. This invention provides a novel synergistic drug strategy and a highly biomimetic in vitro evaluation platform for the treatment of liver fibrosis.

The invention relates to a composite nanoparticle VZTM-Gal and a preparation method thereof.According to the VZTM-Gal, efficient loading of a VDAC1 inhibitor VBIT-4 is achieved on the basis of a ZIF-8 nano system, then tannic acid is introduced to be coordinated with exogenous Mg < 2 + > and Zn < 2 + > on the surface of ZIF-8, a metal-polyphenol layer on the surface of ZIF-8 is constructed, and the composite nanoparticle is rapidly disintegrated and released in a lysosome environment; the surface-coupled GalNAc ligand can significantly enhance the specific recognition and uptake of the drug to parenchymal hepatic cells; the preparation process is mild in conditions and simple and convenient in steps, and the obtained nanoparticles are uniform in particle size; the invention further relates to application of the VZTM-Gal in treatment of cadmium-induced acute liver injury and non-alcoholic steatohepatitis induced by combined choline deficiency L-amino acid limited high fat diet exposure, experiments prove that VBIT-4 released by the VZTM-Gal can inhibit VDAC1 oligomerization and inhibit mitochondrial excessive autophagy, tannic acid can remove active oxygen, and the VZTM-Gal can be used for treating cadmium-induced acute liver injury and non-alcoholic steatohepatitis induced by choline deficiency L-amino acid limited high fat diet exposure. Mg < 2 + > synergistically reduces calcium overload caused by cadmium, recovers mitochondrial morphology and functions, and improves liver functions.

The invention discloses an application of polypeptide in prevention and treatment of plateau hepatic lipid accumulation. The amino acid sequence of the polypeptide is shown as SEQ ID NO.1. The polypeptide effectively blocks abnormal lipid deposition in parenchymal liver cells and macrophages in the plateau low-oxygen environment by competitively inhibiting the function of endogenous CIRP. Animal and cell experiments show that the polypeptide can significantly improve liver fatty degeneration caused by plateau exposure, thereby providing a brand new targeted therapy strategy and drug candidate for prevention and treatment of plateau-related non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and hepatocellular carcinoma (HCC).

The invention discloses a multi-organ regulation and control combined nano preparation and application thereof, and belongs to the technical field of medicines. The combined nano preparation consists of a nano preparation A and a nano preparation B, the nano preparation A is a parenchymal hepatic cell regulation and control nano delivery system and is prepared from phospholipid, cholesterol, PEGylated phospholipid, DSPE-PEG-Glactase and a THR-beta agonist; and the nano preparation B is an adipose cell regulation and control nano delivery system and is prepared from phospholipid, cholesterol, PEGylated phospholipid, DSPE-PEG-CKGGRAKDC and a PPAR gamma agonist. According to the invention, malignant crosstalk formed by liver-adipose tissue axes is utilized for the first time, and a strategy for treating fatty hepatitis and hepatic fibrosis related to metabolic dysfunction by cooperatively regulating lipid metabolism balance between two organs of liver and fat by using two types of liposomes is innovatively provided; the invention provides a new strategy and way for treating metabolic liver diseases.

The invention discloses a preparation method and application of a large-size human liver organ. Belongs to the technical field of cell culture. The method comprises the following steps: re-suspending 2D cultured mature human primary parenchymal hepatic cells with different cell quantities by using a hepatic cell maturation culture medium HIM, adding the re-suspended cells into a 96-well plate with a U-shaped bottom, carrying out low-oxygen standing culture, and carrying out normal-oxygen shaking culture after the cells are gathered, so as to prepare the large-size human liver organs with different cell contents. According to the method, biological materials are not needed, the human primary parenchymal hepatic cells are induced to be self-assembled through specific culture conditions to construct functional liver organs with highly uniform dimensions, and the problems of large batch difference, high heterogeneity and dedifferentiation in the prior art are solved; the method can be widely applied to drug hepatotoxicity testing, liver disease in-vitro modeling and bioartificial liver system development.

The invention provides an oridonin drug delivery system of a targeted hepatic-cerebral axis as well as a preparation method and application of the oridonin drug delivery system, and belongs to the technical field of biological medicines and nano-medicines. The drug delivery system is prepared by entrapment of oridonin in apoferritin. The preparation method comprises the following steps: dispersing apoferritin in an acetone solution to obtain an apoferritin solution; and adding oridonin into the deferritin solution, stirring, filtering, and centrifuging to obtain the oridonin drug delivery system. According to the invention, the solubility of the oridonin and the targeting to brain tissues and livers are improved, and the effect of the oridonin as a medicine for treating AD is enhanced. The expression of brain capillary endothelial cells LRP-1 is also improved, the excretion of A beta from the brain is promoted, and the neuronal mitochondrial dysfunction is relieved, so that the neuronal injury is relieved. The traditional Chinese medicine composition also improves the expression of parenchymal liver cells LRP-1, promotes Abeta removal, inhibits liver inflammation, reduces accumulation of inflammatory factors in the brain, and synergistically protects neurons.

The invention belongs to the field of medical application of birch juice, and discloses application of a birch juice separating medium to improvement of parenchymal hepatic cell injury, the birch juice separating medium is used for improving parenchymal hepatic cell injury, and the birch juice separating medium is prepared according to the following steps: S1, raw material pretreatment; s2, preliminary filtration; s3, performing ultrafiltration; s4, performing nanofiltration concentration; s5, chromatographic purification; s6, vacuum drying; according to the technical scheme, the birch juice separation liquid is applied to improvement of the parenchymal hepatic cell injury, the parenchymal hepatic cell injury is improved through the birch juice separation liquid, the application field of the birch juice is expanded, and experiments show that the birch juice separation liquid prepared through the technical scheme can remarkably reduce transaminase release of the injured parenchymal hepatic cells, so that the survival rate of the injured parenchymal hepatic cells is increased. The traditional Chinese medicine composition has the advantages that the activity of antioxidant enzymes is improved, the content of lipid peroxidation products is reduced, and the traditional Chinese medicine composition has a good improvement effect on parenchymal hepatic cell injury induced by various factors and provides a new natural active substance source for preventing and treating liver injury.

The application provides a preparation method and application of a liver tumor tissue single-cell suspension, and the preparation method comprises the following steps: step 1, pretreating liver tumor tissue; step 2, step-by-step enzymolysis; the pretreated liver tumor tissue in step 1 is subjected to step-by-step enzymolysis by using an enzyme solution, and the enzyme solution in each step is collected after filtration to obtain a cell suspension; step 3, gradient centrifugation; the cell suspension is subjected to gradient centrifugation by using a cell separation solution to separate immune cells and liver parenchymal cells; step 4, red blood cell lysis; the immune cells obtained in step 3 are subjected to red blood cell lysis by using a red blood cell lysis solution, and centrifugal washing is carried out to obtain an immune cell precipitate; step 5, collecting the liver parenchymal cells in step 3 and the immune cell precipitate in step 4, washing the liver parenchymal cells and the immune cell precipitate by using a cell washing solution, centrifuging to obtain a cell precipitate, resuspending the cell precipitate by using a cell resuspension solution, and filtering to obtain the liver tumor tissue single-cell suspension.

According to the application of the DDX6 inhibitor in preparing the medicine for treating the diseases related to the rising of the cholesterol, the function of the DDX6 gene in parenchymal hepatic cells is inhibited by means of gene knockout, the content of the cholesterol in mouse blood can be effectively reduced, and the damage to liver tissue is avoided. Furthermore, the influence of DDX6 on the liver is analyzed through transcriptome sequencing, and it is found that DDX6 knockout is likely to play a role by inhibiting synthesis of cholesterol in parenchymal hepatic cells.

The invention relates to the technical field of biology, in particular to a mouse liver cell extraction and cryopreservation method. Comprising the following steps: performing liver perfusion and digestion: performing inferior vena cava intubation on a mouse corpse, cutting open vena cava, clamping superior vena cava, performing perfusion with perfusate for 6-8 minutes, and performing circulating perfusion with digestive juice for 10-15 minutes; separating and purifying the cells: taking out the liver, tearing a liver membrane in precooling termination digestion liquid at 3-5 DEG C, filtering by a screen, collecting filtrate, performing primary centrifugation on the filtrate, supplementing a complete culture medium, then performing secondary centrifugation, collecting cell precipitates, washing with the complete culture medium for 2-3 times, performing centrifugation again, and retaining the cell precipitates at the bottom to obtain purified parenchymal liver cells; and resuspending the purified parenchymal hepatic cells by using a precooled cryopreservation solution until the final concentration is (1-2) * 10 < 7 > cells / mL, sub-packaging and cryopreserving. The method is stable in operation, high in cell obtaining rate, good in activity and high in recovery rate after cryopreservation.